{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T03:28:43Z","timestamp":1794194923400,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13555-025-01416-z","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T09:30:17Z","timestamp":1745400617000},"page":"1427-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg\u2014IL PSO (Italian Landscape Psoriasis)"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Cagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia V.","family":"Di Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Licata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo R.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rapparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Zichichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pina","family":"Brianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"9997","key":"1416_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Lancet"},{"issue":"19","key":"1416_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"1416_CR3","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","volume":"16","author":"M Valenti","year":"2022","unstructured":"Valenti M, Narcisi A, Pavia G, Gargiulo L, Costanzo A. What can IBD specialists learn from IL-23 trials in dermatology? J Crohns Colitis. 2022;16(Suppl 2):ii20\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac023.","journal-title":"J Crohns Colitis"},{"key":"1416_CR4","unstructured":"European Medicines Agency. Ilumetri (tildrakizumab): summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri. Accessed 2025 Feb 12."},{"issue":"4","key":"1416_CR5","doi-asserted-by":"publisher","first-page":"e2024284","DOI":"10.5826\/dpc.1404a284zzz","volume":"14","author":"EV Di Brizzi","year":"2024","unstructured":"Di Brizzi EV, Caccavale S, Di Caprio R, et al. A prospective real-life multicenter study of tildrakizumab 200\u00a0mg in patients with moderate-severe psoriasis: who is the ideal patient? Dermatol Pract Concept. 2024;14(4):e2024284. https:\/\/doi.org\/10.5826\/dpc.1404a284zzz.","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"1416_CR6","doi-asserted-by":"publisher","first-page":"2350760","DOI":"10.1080\/09546634.2024.2350760","volume":"35","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, CascioIngurgio R, et al. Comparative effectiveness of tildrakizumab 200\u00a0mg versus tildrakizumab 100\u00a0mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis). J Dermatolog Treat. 2024;35(1):2350760. https:\/\/doi.org\/10.1080\/09546634.2024.2350760.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1416_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2024.2325547","volume":"24","author":"P Dapavo","year":"2024","unstructured":"Dapavo P, Burlando M, Guarneri C, et al. Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden. Expert Opin Biol Ther. 2024;24(3):133\u20138. https:\/\/doi.org\/10.1080\/14712598.2024.2325547.","journal-title":"Expert Opin Biol Ther"},{"issue":"10091","key":"1416_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase\u00a03 trials. Lancet. 2017;390(10091):276\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(17)31279-5.","journal-title":"Lancet"},{"issue":"10","key":"1416_CR9","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13555-022-00793-z","volume":"12","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5\u00a0years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325\u201341. https:\/\/doi.org\/10.1007\/s13555-022-00793-z.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1416_CR10","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3390\/medicina59112006","volume":"59","author":"A Czarnecka","year":"2023","unstructured":"Czarnecka A, Zab\u0142otna M, Purzycka-Bohdan D, Nowicki RJ, Szczerkowska-Dobosz A. An observational study of 147 psoriasis patients: overweightness and obesity as a significant clinical factors correlated with psoriasis. Medicina. 2023;59(11):2006. https:\/\/doi.org\/10.3390\/medicina59112006.","journal-title":"Medicina"},{"issue":"1","key":"1416_CR11","doi-asserted-by":"publisher","first-page":"2425029","DOI":"10.1080\/09546634.2024.2425029","volume":"35","author":"L Ibba","year":"2024","unstructured":"Ibba L, Di Giulio S, Gargiulo L, et al. Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study. J Dermatolog Treat. 2024;35(1):2425029. https:\/\/doi.org\/10.1080\/09546634.2024.2425029.","journal-title":"J Dermatolog Treat"},{"key":"1416_CR12","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DMSO.S405374","volume":"16","author":"A Di Vincenzo","year":"2023","unstructured":"Di Vincenzo A, Granzotto M, Crescenzi M, et al. Insulin stimulates IL-23 expression in human adipocytes: a possible explanation for the higher prevalence of psoriasis in obesity. Diabetes Metab Syndr Obes. 2023;16:1885\u201393. https:\/\/doi.org\/10.2147\/DMSO.S405374.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1416_CR13","first-page":"491722s4","volume":"24","author":"L Guo","year":"2025","unstructured":"Guo L, Kircik L, Armstrong AW. INDIVIDUAL ARTICLE: Psoriasis and obesity: optimizing pharmacologic treatment and lifestyle interventions. J Drugs Dermatol. 2025;24(1):491722s4\u201314.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1416_CR14","doi-asserted-by":"publisher","first-page":"2420825","DOI":"10.1080\/09546634.2024.2420825","volume":"35","author":"A Dattola","year":"2024","unstructured":"Dattola A, Bernardini N, Svara F, et al. Effectiveness of tildrakizumab 200\u00a0mg: an Italian multicenter study. J Dermatolog Treat. 2024;35(1):2420825. https:\/\/doi.org\/10.1080\/09546634.2024.2420825.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1416_CR15","doi-asserted-by":"publisher","first-page":"2199108","DOI":"10.1080\/09546634.2023.2199108","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023;34(1):2199108. https:\/\/doi.org\/10.1080\/09546634.2023.2199108.","journal-title":"J Dermatolog Treat"},{"issue":"Suppl 1","key":"1416_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","volume":"157","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl 1):1\u201378. https:\/\/doi.org\/10.23736\/S2784-8671.21.07132-2.","journal-title":"Ital J Dermatol Venerol"},{"issue":"6","key":"1416_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","volume":"232","author":"P Jensen","year":"2016","unstructured":"Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633\u20139. https:\/\/doi.org\/10.1159\/000455840.","journal-title":"Dermatology"},{"issue":"6","key":"1416_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jdv.15400","volume":"33","author":"KA Papp","year":"2019","unstructured":"Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks\u00a012 and 28. J Eur Acad Dermatol Venereol. 2019;33(6):1098\u2013106. https:\/\/doi.org\/10.1111\/jdv.15400.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1416_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","volume":"11","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Soliman AM, Betts KA, et al. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2021;11(3):885\u2013905. https:\/\/doi.org\/10.1007\/s13555-021-00511-1.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1416_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/1346-8138.15789","volume":"48","author":"A Igarashi","year":"2021","unstructured":"Igarashi A, Nakagawa H, Morita A, et al. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 64-week phase\u00a03 study (reSURFACE 1). J Dermatol. 2021;48(6):853\u201363. https:\/\/doi.org\/10.1111\/1346-8138.15789.","journal-title":"J Dermatol"},{"issue":"1","key":"1416_CR21","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/jdv.19464","volume":"38","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2024;38(1):e113\u20136. https:\/\/doi.org\/10.1111\/jdv.19464.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1416_CR22","doi-asserted-by":"publisher","first-page":"711060","DOI":"10.3389\/fimmu.2021.711060","volume":"12","author":"Y Hao","year":"2021","unstructured":"Hao Y, Zhu YJ, Zou S, et al. Metabolic syndrome and psoriasis: mechanisms and future directions. Front Immunol. 2021;12:711060. https:\/\/doi.org\/10.3389\/fimmu.2021.711060.","journal-title":"Front Immunol"},{"issue":"1","key":"1416_CR23","doi-asserted-by":"publisher","first-page":"2291323","DOI":"10.1080\/09546634.2023.2291323","volume":"35","author":"S Cacciapuoti","year":"2024","unstructured":"Cacciapuoti S, Megna M, Salza E, Potestio L, Caiazzo G. The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study. J Dermatolog Treat. 2024;35(1):2291323. https:\/\/doi.org\/10.1080\/09546634.2023.2291323.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1416_CR24","doi-asserted-by":"publisher","first-page":"2241585","DOI":"10.1080\/09546634.2023.2241585","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Vignoli CA, et al. Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study. J Dermatolog Treat. 2023;34(1):2241585. https:\/\/doi.org\/10.1080\/09546634.2023.2241585.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01416-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T12:48:37Z","timestamp":1747745317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01416-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1416"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01416-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, and Boehringer Ingelheim. Mario Valenti is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Luciano Ibba has been a consultant for Almirall. Luigi Gargiulo has been a consultant and\/or speaker for Abbvie, Almirall, Eli Lilly, Pfizer, Sanofi and UCB Pharma. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma, and Almirall. Anna Balato has received honoraria for participation in advisory boards, meetings, or as a speaker for AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, Sanofi-Genzyme, and UCB Pharma. Federico Bardazzi has been a consultant adviser and clinical study investigator for Eli Lilly, AbbVie, Novartis, Leo Pharma, Sandoz, Bristol Myers, Abiogen-Pharma, Celgene, and Janssen. Martina Burlando has acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, and UCB Pharma. Carlo G. Carrera has served as a board participant or speaker for AbbVie, Eli Lilly, Janssen, Novartis, Celgene, Almirall, and Leo Pharma. Andrea Carugno has been a consultant and\/or speaker for AbbVie, Leo Pharma, Eli Lilly, Novartis, Janssen-Cilag, Amgen, Almirall, UCB Pharma, and Boehringer Ingelheim. Paolo Dapavo has been a speaker for Novartis, AbbVie, Sanofi, UCB, Janssen, Eli Lilly, and Leo Pharma. Maria Concetta Fargnoli has served as a consultant\/advisor, received speaker honoraria and\/or grants, and\/or is an investigator for Amgen, Almirall, AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Kyowa Kirin, Incyte, Leo Pharma, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi, Regeneron, Sun Pharma, and Takeda. Francesca M. Gaiani acted as a speaker or consultant for Novartis, AbbVie, Eli Lilly, Celgene, Leo Pharma, and Almirall. Claudio Guarneri has been a scientific consultant, speaker, and clinical study investigator for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Almirall, and Leo Pharma. Claudia Lasagni declares a conflict of interest with AbbVie, Novartis, Eli Lilly, and Almirall. Francesco Loconsole served on advisory boards and\/or received honoraria for lectures from Abbvie, Janssen-Cilag, Novartis, Lilly, Sanofi. Angelo V. Marzano reports consultancy\/advisory board disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, and UCB. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, Janssen, Leo Pharma, and Novartis. Diego Orsini has been a speaker and\/or consultant for AbbVie, Leo Pharma, UCB, Bristol-Myers Squibb, and Boehringer Ingelheim. Simone Ribero has served as an advisory board member and\/or consultant and has received fees and speaker\u2019s honoraria or has participated in clinical studies for AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, and Sanofi Genzyme. Davide Strippoli has been a consultant and\/or speaker for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. Emanuele Trovato is involved in an intermittent project focused on consulting and\/or advisory relationships and\/or travel-congress support with Eli Lilly, Novartis, Janssen-Cilag, AbbVie, and Almirall. Marina Venturini served as a speaker or advisory board member for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. Leonardo Zichichi has received grants for scientific contributions from AbbVie, Almirall, Amgen, Eli Lilly, and Novartis. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Sara Di Giulio, Pina Brianti, Anna E. Cagni, Norma Cameli, Aldo Cuccia, Eugenia V. Di Brizzi, Valentina Dini, Gaetano Licata, Santo R. Mercuri, Alessandra Michelucci, Maria L. Muscumesi, Romina Ortega, Luca Potestio, Luca Rapparini, and Francesca Satolli have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval was exempted as the study protocol did not deviate from standard clinical practice. All patients received tildrakizumab as in good clinical practice, in accordance with European guidelines. All included patients had provided written consent for retrospective study of data collected during routine clinical practice (demographics, clinical scores). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}